ASH China Voice | Jia Wei’s Team Presents Seven Studies at ASH 2025, Advancing Multi-Dimensional Exploration of Therapeutic Bottlenecks in Hematologic

ASH China Voice | Jia Wei’s Team Presents Seven Studies at ASH 2025, Advancing Multi-Dimensional Exploration of Therapeutic Bottlenecks in Hematologic

2025.12.10
From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando. As the world’s most influential and comprehensive academic event in hematology, ASH annually gathers tens of thousands of experts to present breakthroughs spanning basic research to clinical innovation. This year, the team led by Professor Jia Wei of Tongji Hospital, Huazhong University of Science and Technology, had seven studies accepted—one oral presentation and six posters—covering CAR-T therapy, multi-omics analysis and immunotherapy. These studies collectively illustrate a full-spectrum innovation pipeline from mechanistic discovery to translational clinical application. Hematology Frontier summarizes the key findings below and presents Professor Wei’s commentary on their broader significance.
ESMO25 Highlight | Insights from Dr. Darren M. Poon

ESMO25 Highlight | Insights from Dr. Darren M. Poon

2025.12.10
At the recent ESMO Asia 2025 Congress, a study by Professor Darren Poon's team at the Hong Kong Comprehensive Oncology Centre was selected, bringing a new precision medicine strategy to patients with advanced prostate cancer. Oncology Frontier- UroStream invited Professor Poon to share his insights on the clinical value and future prospects of liquid biopsy for Chinese patients with androgen receptor ligand binding domain-mutated prostate cancer. #ESMOAsia2025 #prostatecancer #precisionmedicine
SIBCS 2025丨Feng Jin: China’s Breast Cancer Clinical Research Enters a New Era of Systematic Innovation Driven by Precision Medicine and Domestic Drug Development 

SIBCS 2025丨Feng Jin: China’s Breast Cancer Clinical Research Enters a New Era of Systematic Innovation Driven by Precision Medicine and Domestic Drug Development 

2025.12.09
The 20th Shanghai International Breast Cancer Symposium (SIBCS), jointly organized by the Shanghai Anti-Cancer Association and the Breast Cancer Committee of the China Anti-Cancer Association, was recently held in Shanghai. Under the theme “20 Years of Progress, a Future of Continuity”, the forum brought together leading experts from China and abroad to reflect on two decades of advances in breast cancer diagnosis and treatment in China. During the “Year in Review” session, Professor Feng Jin of the First Hospital of China Medical University delivered a presentation titled “Key Clinical Trial Achievements in Chinese Breast Cancer Research.” Oncology Frontier invited Professor Jin for an in-depth discussion on China’s breakthrough clinical evidence, its global impact, and China’s future developmental directions in breast cancer research.
SIBCS 2025丨Jun-jie Li: Riding China’s Wave of Innovation—Leveraging the SIBCS Platform to Drive Comprehensive Advances in Breast Cancer Care

SIBCS 2025丨Jun-jie Li: Riding China’s Wave of Innovation—Leveraging the SIBCS Platform to Drive Comprehensive Advances in Breast Cancer Care

2025.12.09
The 20th Shanghai International Breast Cancer Symposium (SIBCS), jointly hosted by the Shanghai Anti-Cancer Association and the Breast Cancer Committee of the China Anti-Cancer Association, was held from November 13–15, 2025 in Shanghai. During the meeting, Professor Jun-jie Li from Fudan University Shanghai Cancer Center delivered a keynote lecture entitled “Two Decades of Shared Progress: The Journey of China’s Original Innovation and the Rise of SIBCS.” Following the presentation, Oncology Frontier interviewed Professor Li to further discuss the latest advances of China’s original innovative drugs in breast cancer, and to explore how SIBCS enables cross-generational academic exchange and fosters synergistic development between Chinese innovations and the SIBCS platform.
ESMO China–International Dialogue | Meeting at the Summit: How China’s Innovative ADCs sac-TMT and A166 Are Reshaping the Breast Cancer Treatment Landscape 

ESMO China–International Dialogue | Meeting at the Summit: How China’s Innovative ADCs sac-TMT and A166 Are Reshaping the Breast Cancer Treatment Landscape 

2025.12.08
 At the 2025 European Society for Medical Oncology (ESMO) Annual Congress, Chinese innovative drugs and clinical research drew global attention. During the meeting, Xichun Hu, Professor at Fudan University Shanghai Cancer Center, presented a Late-Breaking Abstract (LBA) detailing the pivotal phase III study in which China’s first original HER2-targeted antibody–drug conjugate (ADC), A166 (budotituzumab vedotin), successfully challenged T-DM1 in the second-line setting for HER2-positive breast cancer. Based on this study, A166 received approval from the National Medical Products Administration (NMPA) on October 17, 2025, bringing a new standard-of-care option to clinical practice.